Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Abstract Background Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. Methods ER-positive early breast cancer patients operated at Ruij...

Full description

Bibliographic Details
Main Authors: Shuai Li, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Cancer
Subjects:
Breast cancer
Hormone receptor
HER2
Trastuzumab
Endocrine therapy
Escalation
Online Access:https://doi.org/10.1186/s12885-021-08555-4

Internet

https://doi.org/10.1186/s12885-021-08555-4

Similar Items